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Abstract
Background: Endothelial function is a prognostic predictor in patients undergoing percutaneous coronary
intervention (PCI). However, in an era with widespread use of drug-eluting stents, the clinical relevance of
endothelial dysfunction on restenosis in patients undergoing PCI has not been fully evaluated.
Methods: This study included 80 patients with stable angina pectoris. Flow-mediated dilation (FMD) of the brachial
artery was examined 1 week after PCI. Patients were retrospectively followed-up for an average of 21 months after
PCI. The primary endpoints included cardiac death, nonfatal myocardial infarction, stroke, coronary revascularization,
and critical limb ischemia.
Results: A drug-eluting stent was used in 58 patients and a cardiovascular event was recorded in 34 patients
during follow-up. The incidence of all cardiovascular diseases was significantly greater in the low FMD (median
FMD <4.2 %) than the high FMD (median FMD ≥4.2 %) group (60 % vs. 25 %, p <0.01). Furthermore, the incidence
of coronary revascularization was significantly higher in the low than the high FMD group (p = 0.02), while the incidence
of in-stent restenosis did not differ between the two groups. Cox regression analysis showed that low FMD was an
independent predictor of cardiovascular events (hazard ratio: 2.77, 95 % confidence interval: 1.23 to 6.19, p = 0.01).
Conclusions: Impaired brachial artery FMD independently predicts long-term cardiovascular events after PCI in the era
of drug-eluting stents.
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Background
Endothelial dysfunction leads to the initiation of athero-
sclerosis and is linked to many risk factors that predis-
pose individuals to atherosclerosis [1–3]. Noninvasive
ultrasound assessment of brachial artery flow-mediated
dilation (FMD) has emerged as a method for studying
nitric-oxide-dependent endothelial function [4]. Although
reproducible FMD measurements require careful atten-
tion to training, technique, and analysis [5], previous
studies have shown that FMD is a predictor of future
cardiovascular events in populations with coronary risk
factors [6, 7], and in patients with established coronary
artery disease (CAD) [8, 9].
Percutaneous coronary intervention (PCI) with stent-
ing is currently an effective and widespread treatment
for patients with CAD. Although in-stent restenosis is a
limitation of PCI, the use of drug-eluting stents (DES)
has dramatically reduced the risk of restenosis [10].
Previous studies have shown that impaired FMD is a
predictor of in-stent restenosis and cardiovascular events
in patients undergoing PCI [11–14]. However, the use
of DES modifies the association between endothelial
function and in-stent restenosis because a drug released
from the stent struts strongly suppresses the re-growth
of endothelial cells onto stent struts [15]. Owing to the
widespread use of DES in PCI, the association between
impaired endothelial function and prognosis in patients
undergoing PCI, including in-stent restenosis, needs to
be re-evaluated.
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We investigated whether early assessment of FMD
predicts cardiovascular events, including in-stent re-
stenosis, in patients undergoing PCI in the era of DES.
Methods
Study patients
This study enrolled 80 patients from among 138 con-
secutive patients with stable angina who were admitted
to Okayama University Hospital for PCI and joined a
cardiac rehabilitation program from August 2008 to
February 2014. Patients who had angiographic documen-
tation of organic stenosis of >70 % of at least one major
coronary artery and had PCI successfully performed
were eligible. Patients were excluded based on the pres-
ence of any of the following criteria: 1) acute coronary
syndrome; 2) prior myocardial infarction; 3) history of
stroke; 4) New York Heart Association functional
classification ≥ III; 5) left main trunk disease; 6) left
ventricular ejection fraction on echocardiography <40 %; 7)
malignant disease; 8) chronic hepatic disease; 9) chronic in-
flammatory diseases; 10) chronic renal failure (serum cre-
atinine levels >2.0 mg/dl); and 11) other serious systemic
diseases. This study was approved by the institutional
ethics committee of Okayama University Hospital. Written
informed consent was provided by all of the patients before
the study. The investigation conformed to the principles
outlined in the Declaration of Helsinki.
Study protocol
Measurement of FMD was performed in the morning
after an overnight fast in the same manner at 1 week
after PCI. All vasodilators were withdrawn 24 h before
the FMD measurements. After PCI, all patients had indi-
vidualized, optimized therapies, including medications
and lifestyle changes, to reduce risk factors for CAD ac-
cording to the American College of Cardiology/American
Heart Association guidelines [16]. Levels of serum lipids,
hemoglobin A1c, malondialdehyde-modified low-density
lipoprotein (LDL) cholesterol, C-reactive protein, and adi-
ponectin were measured, as described previously [17]. Pa-
tients were then retrospectively followed after PCI.
PCI
PCI was performed with conventional techniques by the
femoral or radial approach under systemic heparinization,
and oral administration of aspirin and ticlopidine. The
stent type and inflation pressure were chosen at the dis-
cretion of the physicians, who were blinded to the study
protocol and the data regarding FMD. Procedural success
was defined as reduction of stenosis to <30 % residual
narrowing, with improvement of ischemic symptoms and
without major in-hospital complications, such as death,
emergency bypass surgery, or myocardial infarction (de-
fined as >5 times increase in cardiac troponin T levels).
After PCI, patients received aspirin (100 mg/day) indefin-
itely and ticlopidine (200 mg/day) or clopidogrel (75 mg/
day) for at least 9 months. Original stented target lesion
revascularization was defined as repeated PCI, and was
performed in the presence of in-stent restenosis and any
symptoms or objective signs of myocardial ischemia.
Measurements of FMD in the brachial artery
FMD was assessed as a parameter of vasodilation ac-
cording to the guidelines for ultrasound assessment [4].
Using a 10-MHz linear-array transducer probe (Unex
Company Ltd., Nagoya, Japan), longitudinal images of
the brachial artery at baseline were recorded with a stereo-
tactic arm, and measurements of the arterial diameter
were made after supine rest for ≥5 min. The diameter of
the artery was measured, then suprasystolic compression
(50 mmHg higher than systolic blood pressure) was per-
formed at the right forearm for 5 min. Measurements
of the arterial diameter were made continuously from
30 s after cuff release. Maximum vasodilation was then
evaluated from the change in arterial diameter after re-
lease of occlusion. An experienced technician blinded
to the clinical data of the study participants measured
FMD and intra- and inter-observer correlation coeffi-
cients were high (>0.9) [18].
Follow-up study
The primary endpoints included cardiac death, nonfatal
myocardial infarction, coronary revascularization, critical
limb ischemia, and stroke. The time to the first primary
endpoint was evaluated retrospectively. The definition
and assessment of endpoints were based on the state-
ment from the American College of Cardiology/Ameri-
can Heart Association Task Force [19]. Myocardial
infarction was defined as type 1 or type 2 myocardial in-
farction according to the Third Universal Definition of
Myocardial Infarction [20]. All elective coronary revas-
cularizations were undertaken only if the invasive frac-
tional flow reserve of a coronary lesion was 0.80 or less
[21]. Stroke included both ischemic and hemorrhagic
types. Peripheral vascular intervention was documented
in a Report of the American College of Cardiology/
American Heart Association Task Force on Clinical Data
Standards [20]. Critical limb ischemia needs emergency
vascular intervention. Therefore, we included critical
limb ischemia as a cardiovascular endpoint in this study.
Data regarding primary and secondary outcomes were
carefully collected from clinical charts and the diagnosis
was confirmed by an investigator who was blinded to
FMD data.
Statistical analysis
Data are expressed as the mean ± standard deviation or
number (percentage). The frequencies and continuous
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values between the two groups of patients were com-
pared using the chi-square test and the Student’s t test,
respectively. Kaplan–Meier analysis of event-free sur-
vival during follow-up was performed on the basis of the
cut-off value of FMD. The association of FMD with fu-
ture events was assessed by Cox proportional hazards
analysis. The data were initially analyzed using a univari-
ate model with covariates, including FMD and other po-
tential confounders that were significantly different
between patients with and without events. Multivariate
Cox proportional hazards analysis was then applied
using covariates that showed p < 0.1 in the univariate
Cox proportional hazards analysis. Based on previous
studies [11–14], we estimated that the incidence of car-
diovascular events, including restenosis, in this study
would be lower than that in previous studies because of
the high use of DES. With an estimated event rate in pa-
tients with low versus high FMD of 30 % versus 4 %, re-
spectively, a population of 80 patients would be needed
to detect this difference with α = 0.05 and a power of
0.80. p < 0.05 was considered statistically significant.
Statistical analysis was performed using SPSS 17.0 for
Windows (SPSS Inc., Chicago, IL, USA).
Results
A flow diagram of this study is shown in Fig. 1. Of 632 pa-
tients who underwent PCI from August 2008 to February
2014, we excluded 494 patients without FMD data. Of the
138 remaining patients, 58 patients were excluded because
of acute coronary syndrome (n = 24), coronary artery by-
pass graft (n = 16), FMD measured over 1 week after PCI
(n = 16), and lost to follow-up (n = 2). Finally, 80 patients
were analyzed.
The clinical characteristics of patients with and with-
out an event are shown in Table 1. In this study, 56.3 %
of patients had diabetes mellitus and 43.8 % had renal
insufficiency. All of the patients were divided into two
groups: the high FMD group (FMD ≥4.2 %, n = 40) and
the low FMD group (FMD <4.2 %, n = 40), according to
the median value of FMD. Patients with low FMD had
lower high-density lipoprotein (HDL) cholesterol levels
than those with high FMD (p = 0.04). Patients with low
FMD tended to have greater body mass index and higher
triglyceride levels than those with high FMD. There was
no difference in prescription rates for angiotensin-
converting enzyme (ACE) inhibitors and angiotensin II
Fig. 1 Flow diagram showing patients’ acceptance into the study
Table 1 Clinical characteristics in patients with FMD <4.2 %
and ≥4.2 %
FMD <4.2 %




Age (years) 69.5 ± 7.1 69.4 ± 7.3 0.96
Female gender, n (%) 34 (85.0) 30 (75.0) 0.26
Body mass index 25.1 ± 3.4 23.6 ± 3.3 0.06
Diabetes mellitus, n (%) 23 (57.5) 22 (55.0) 0.82
Hypertension, n (%) 27 (65.7) 27 (67.5) 1.00
Dyslipidemia, n (%) 22 (55.0) 31 (77.5) 0.03
Current smoking, n (%) 10 (25.0) 11 (27.5) 0.80
Chronic renal
insufficiency, n (%)
16 (40.0) 19 (47.5) 0.50
Previous PCI, n (%) 5 (12.5) 10 (25.0) 0.15
Previous myocardial
infarction, n (%)
2 (5.0) 2 (5.0) 1.00
HDL cholesterol (mg/dl) 43.8 ± 11.2 49.3 ± 12.3 0.04
LDL cholesterol (mg/dl) 87.8 ± 28.1 88.1 ± 24.6 0.96
Triglycerides (mg/dl) 142.9 ± 73.6 113.7 ± 61.6 0.06
MDA-LDL cholesterol 97.9 ± 36.8 (n = 33) 82.2 ± 32.0 (n = 27) 0.62
Adiponectin 11.3 ± 5.2 12.0 ± 5.3 0.90
Medications
Aspirin, n (%) 40 (100) 38 (95.0) 0.15
Clopidogrel, n (%) 35 (87.5) 33 (82.5) 0.53
ACE inhibitor/ARB, n (%) 35 (87.5) 30 (75.0) 0.15
ARB, n (%) 31 (77.5) 25 (62.5) 0.22
ACE inhibitors, n (%) 4 (10.0) 5 (12.5) 0.99
Perindopril 2 (5.0) 1 (2.5) 0.99
Imidapril 2 (5.0) 4 (10.0) 0.67
Statins, n (%) 36 (90.0) 36 (90.0) 1.00
Atorvastatin 4 (10.0) 7 (17.5) 0.52
Rosuvastatin 18 (45.0) 16 (40.0) 0.82
Pitavastaitn 14 (35.0) 13 (32.5) 0.99
β-blockers, n (%) 21 (52.5) 25(62.5) 0.37
Data are expressed as mean ± SD or number (percentage)
FMD Flow-mediated dilation, PCI Percutaneous coronary intervention,
HDL High-density lipoprotein, LDL low-density lipoprotein, MDA-LDL
Malondialdehyde-modified low-density lipoprotein, ACE Angiotensin-
converting enzyme, ARB Angiotensin II receptor blocker
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receptor blockers (ARBs) between the two FMD groups.
Additionally, there was no difference in the type of
ACE inhibitors between the two groups. There was
also no difference in the type of statins between the
two groups.
Procedural features of PCI are shown in Table 2.
The percentage of the left anterior descending coron-
ary artery as a target vessel artery was greater in the
high FMD group than the low FMD group. The use
of DES was 68 % in the low FMD group and 78 % in
the high FMD group (p = 0.32). There were no differ-
ences in PCI-related features, such as lesion type,
number of stents per lesion, stent diameter, stent
length, and stent deployment pressure between the
low and high FMD groups.
Patients were retrospectively analyzed for a mean of
21.4 ± 15.9 months after PCI. Table 3 shows the num-
ber of cardiovascular disease events when patients
were dichotomously categorized as having low FMD
or high FMD. During this follow-up period, 34 pa-
tients had a cardiovascular event, including cardiac
death (n = 1), coronary revascularization (n = 28), crit-
ical limb ischemia (n = 1), or ischemic stroke (n = 4). Of
19 patients undergoing coronary revascularization due to
new lesions, two patients in the low FMD group were hos-
pitalized for unstable angina, but were not diagnosed as
having myocardial infarction. PCI for new lesions in the
low FMD group was performed significantly more fre-
quently than that in the high FMD group, whereas target
lesion revascularization was not different between the
groups. FMD in patients with cardiovascular events
(n = 34) was significantly lower than that in patients
without cardiovascular events (n = 46) (3.4 ± 1.2 vs 5.1 ±
1.8, p < 0.01). There was no difference in the diameter of
the brachial artery at baseline and after administration
of nitroglycerin between patients with and without
cardiovascular disease. The event-free survival curves
are shown in Fig. 2. Patients in the low FMD group
had significantly more events than those in the high
FMD group (p < 0.01). In the Cox proportional haz-
ards model including β-blockers and FMD, low FMD
(<4.2 %) remained an independent predictor of car-
diovascular events (Table 4).
Discussion
This study shows that impairment of brachial artery
FMD is an independent predictor of cardiovascular
events, especially revascularization; however, the brachial
artery FMD did not predict in-stent restenosis. Our find-
ings suggest that early evaluation of endothelial function
of the brachial artery after PCI can predict cardiovascu-
lar events, even in the era of DES.
Our results are in line with previous findings that im-
paired FMD of the brachial artery is associated with ad-
verse outcomes in patients undergoing coronary stent
implantation [8, 11–14, 22], but our study has some dif-
ferences. In the studies by Patti et al. [14] and Munk et
al. [13], the authors reported that impairment of FMD at
30 days after PCI predicted in-stent restenosis in pa-
tients with stable CAD at follow-up, while the use of
DES was 3 % and 21 %, respectively. However, in our
study, almost 70 % of patients were treated with DES.
The mechanisms involved in in-stent restenosis include
platelet and inflammatory cell activation due to proced-
ural vascular injury, leucocyte adherence, smooth muscle
cell proliferation, and extracellular matrix synthesis [23].
Endothelial function affects the association of these fac-
tors with in-stent restenosis of bare metal stents. However,
in the case of DES, the effect of endothelial function on
Table 2 Procedural features in patients with FMD <4.2 %
and ≥4.2 %
FMD <4.2 %
(n = 40 )
FMD≥ 4.2 %
(n = 40 )
p





Left mail trunk, n (%) 3 (7.0) 5 (10.2) 0.46
Left anterior descending,
n (%)
12 (27.9) 25 (51.0) <0.01
Left circumflex, n (%) 16 (37.2) 12 (24.5) 0.35
Right coronary disease,
n (%)
12 (27.9) 7 (14.3) 0.19
Multivessel coronary
disease, n (%)
19 (47.5) 20 (50.0) 0.82
Lesion type B/C2, n (%) 40 (100) 39 (97.5) 0.31
Number of stets per
lesion, n (%)
1.3 ± 0.6 1.3 ± 0.7 0.73
Stent diameter (mm) 3.03 ± 0.55 2.85 ± 0.51 0.13
Total stent length (mm) 22.4 ± 14.2 28.3 ± 16.9 0.09
Use of drug eluting
stent (%)
27 (67.5) 31 (77.5) 0.32
Stent deployment
pressure (atm)
18.3 ± 4.3 18.3 ± 4.5 0.98






Cardiac death, n (%) 1 (2.5) 0 (0) 0.31
Non-fatal myocardial infarction, n (%) 0 (0) 0 (0)
Stroke, n (%) 3 (7.5) 1 (2.5) 0.31
Revascularization, n (%) 19 (47.5) 9 (22.5) 0.02
In stent restenosis, n (%) 5 (12.5) 4 (10.0) 0.72
New lesion, n (%) 14 (35.0) 5 (12.5) 0.02
Critical limb ischemia, n (%) 1 (2.5) 0 (0) 0.31
Total, n (%) 24 (60.0) 10 (25.0) <0.01
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restenosis may be decreased because of strong suppressive
effects of coated drugs on the stents.
Endothelial dysfunction has been proposed to be a
“barometer” of vascular conditions that integrate the
overall effects of risk factors and fundamental defense
mechanisms [24]. Therefore, endothelial function deter-
mined by FMD in the brachial artery could be associated
with the risk of new coronary lesions. In line with this
concept, our study showed a significant association of
FMD with coronary revascularization in new lesions, but
not with in-stent restenosis. Late and very late stent
thrombosis is a serious issue associated with DES [25].
Endothelial dysfunction is significantly associated with
residual platelet aggregability after dual antiplatelet ther-
apy [26]. The observation period of this study was not
sufficient to evaluate late and very late stent thrombosis
of DES. The association between stent thrombosis and
systemic endothelial dysfunction needs to be investigated
in a future large study.
Endothelial function reflects the atherosclerotic risk
burden at the time of its measurement [27–30]. Our
study showed that the low FMD group had lower HDL
cholesterol levels and tended to have higher triglyceride
levels than the high FMD group, while LDL cholesterol
levels were comparable between the two groups. Almost
90 % of our population used statins; therefore, these fac-
tors indicated the exact residual risks of CAD. Low HDL
Fig. 2 Kaplan–Meier survival curves for cardiovascular events in patients
with FMD <4.2 % and ≥4.2 %
Table 4 Univariate and multivariate Cox proportional hazards analyses of risk factors for cardiovascular events
Univariate analysis Multivariate analysis
Relative risk 95 % Confidential interval p Relative risk 95 % Confidential interval p
Age >60 years 0.83 0.29–2.39 0.74
Male 1.07 0.44–2.60 0.88
Diabetes mellitus 1.53 0.76–3.062 0.23
Hypertension 0.95 0.45–2.00 0.89
Dyslipidemia 1.10 0.52–2.31 0.81
Current smoking 1.32 0.64–2.71 0.45
Chronic renal insufficiency 0.62 0.31–1.27 0.19
Previous PCI 0.75 0.290–1.95 0.55
Previous myocardial infarction 0.04 0.00–11.78 0.27
LAD vs LCx/RCA 1.03 0.53–2.02 0.93
Stent diameter <3.0 mm 1.33 0.66–2.67 0.43
Stented segment length > 15mm 1.00 0.49–2.06 1.00
Aspirin 21.14 0.00–159472.77 0.50
Clopidogrel 1.38 0.48–3.93 0.55
ACE inhibitor / ARB 0.98 0.42–2.26 0.98
Statins 1.28 0.30–5.37 0.74
β-blockers 0.50 0.25–1.00 0.05 0.56 0.28–1.13 0.11
FMD <4.2 % 2.60 1.24–5.46 0.01 2.40 1.14–5.06 0.02
PCI Percutaneous coronary intervention, LAD Left anterior descending coronary artery, LCx Left circumflex coronary artery, RCA Right coronary artery,
ACE Angiotensin-converting enzyme, ARB Angiotensin II receptor blocker, FMD Flow-mediated dilation
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cholesterol and high triglyceride levels may contribute to
an increase in small dense LDL [31]. Small dense LDL is
a highly atherogenic lipoprotein, which affects endothe-
lial function [32, 33]. However, endothelial function is
changed by modification of the atherosclerotic risk bur-
den [34, 35]. Our previous study showed that a reduc-
tion in triglyceride levels by ezetimibe improved FMD in
patients with CAD [36]. In terms of risk factor manage-
ment, aggressive interventions for residual risks are
needed to improve endothelial function, leading to an
improvement in the prognosis of patients with CAD.
Endothelial function is affected by several medica-
tions. In terms of inhibition of the renin-angiotensin
system, a significant difference has been observed be-
tween ARBs and ACE inhibitors [37, 38]; some studies
have also suggested a difference between different ACE
inhibitors [39]. In this study, no difference was ob-
served in the prescription rates of ARBs, ACE inhibi-
tors, or the type of ACE inhibitors between the low and
high FMD groups. Statins also improve endothelial
function; however, there may be a difference in the ef-
fect of different types of statins [40]. We have checked
the type of statins used by the study participants, and
no difference in the type of statins was observed be-
tween the two FMD groups. Thus, the use of these
medications is unlikely to have affected the findings of
the current study; however, long-term treatment with
ACE inhibitors and statins may affect clinical outcome
by pleiotropic effects beyond the influence of endothe-
lial function.
Several studies have reported that impairment of
endothelial vasomotor function has an adverse effect on
clinical outcome in patients with CAD [8, 11–14].
However, there is currently no general agreement on
the cut-off value for FMD. Therefore, the application of
FMD in clinical practice is difficult. Currently, a large,
multicenter prospective study is underway to determine
normal values and cut-off values for FMD in the bra-
chial artery, and to assess clinical outcomes [41]. This
study will provide important evidence for the usefulness
of FMD measurements in the risk stratification for car-
diovascular disease.
Recently, use of a bioresorbable vascular scaffold
(BVS) has been reported [42, 43]. The implantation of
a BVS is a new approach that provides transient vessel
mechanical support with drug delivery capability, po-
tentially without permanent metallic implantations. In
the process of bioresorption of the polymeric scaffold,
endothelial function is important for early and appro-
priate covering and replacement of the scaffold by
endothelial cells and extracellular matrix. Further data
relating to the impact of endothelial function on the
prognosis of patients with BVS implantation are
eagerly awaited.
Limitations
First, this study is preliminary and considerably lim-
ited by the small number of study patients. A large
prospective trial is required to determine the precise
role of systemic endothelial function in the pathogenesis
of coronary atherosclerosis. Second, there were relatively
few clinical events compared with the numerous variables
tested in the multivariate model, resulting in large confi-
dence intervals.
Conclusions
This study shows that impaired brachial artery FMD is
an independent determinant of cardiovascular events in
the era of DES. In contrast to previous studies, FMD
was not a predictor of in-stent restenosis in this study.
Our results suggest that early assessment of endothelial
function by brachial artery FMD may represent a useful
screening tool for risk stratification of future cardiovas-
cular events after PCI using DES. Further large prospect-
ive studies are required to evaluate the clinical utility of
a brachial artery FMD method in patients with stable
angina undergoing PCI.
Abbreviation
ACE inhibitor: Angiotensin-converting enzyme inhibitor; ARB: Angiotensin II
receptor blocker; BVS: Bioresorbable vascular scaffold; CAD: Coronary artery
disease; DES: Drug-eluting stent; FMD: Flow-mediated dilation; HDL: High-density
lipoprotein; LDL: Low-density lipoprotein; PCI: Percutaneous coronary intervention.
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